Patents by Inventor Orla M. Conneely

Orla M. Conneely has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Nor-1 and nur77 nuclear receptors as targets for anti-leukemia therapy
    Publication number: 20030220288
    Abstract: The present invention is directed to the application of nuclear receptor transcription factors as molecular targets for therapeutic intervention in the treatment of myeloid leukemia. More specifically, nor-1 and nur77 nuclear receptors are targets for myeloid leukemia therapy.
    Type: Application
    Filed: April 15, 2003
    Publication date: November 27, 2003
    Applicant: Baylor College of Medicine
    Inventors: Shannon E. Mullican, Orla M. Conneely, Jeffrey Milbrandt
  • Production of recombinant lactoferrin and lactoferrin polypeptides using cDNA sequences in various organisms
    Patent number: 6635447
    Abstract: The verified cDNA sequences for human, bovine and porcine lactoferrin protein have been used to prepare recombinant lactoferrin for therapeutic and nutritional applications. Regions of the cDNA such as the Fe binding sites can be used to make an hLF polypeptide product. The present invention provides novel plasmids, transfected eucaryotic cells and methods of producing these plasmids and transfected eucaryotic cells. The novel plasmid contains the cDNA for lactoferrin protein. Methods for the production of lactoferrin protein in fungi and bacteria are also provided. Thus, the present invention provides an efficient and economical means for the production of recombinant lactoferrin protein and lactoferrin related polypeptides.
    Type: Grant
    Filed: August 7, 2000
    Date of Patent: October 21, 2003
    Assignee: Baylor College of Medicine
    Inventors: Orla M. Conneely, Denis R. Headon, Bert W. O'Malley, Gregory S. May
  • LACTOFERRIN AS REGULATOR OF ALLERGEN-INDUCED TUMOR NECROSIS FACTOR-ALPHA PRODUCTION AND THERAPEUTIC APPLICATIONS
    Publication number: 20030190303
    Abstract: The present invention relates to pharmaceutical compositions and methods for treating allergic disorders characterized by a local immune response including inflammatory skin reactions, asthma, and arthritis.
    Type: Application
    Filed: April 10, 1998
    Publication date: October 9, 2003
    Inventors: IAN KIMBER, MARIE CUMBERBATCH, REBECCA J. DEARMAN, ORLA M. CONNEELY, PAULINE WARD
  • Therapeutic approaches to diseases by suppression of the NURR subfamily of nuclear transcription factors
    Publication number: 20020049151
    Abstract: Synovial CRH functions in a paracrine manner to induce the nuclear transcription factor NURR1, which is abundantly expressed in the inflammatory cells of both rheumatoid arthritis and psoriatic arthritis synovium. This induction is suppressed by glucocorticoids. The invention is directed to the pivotal role the NURR subfamily of transcription factors plays in modulation of peripheral CRH and CRH-mediated signaling through the CRH-receptor subtype R1&agr;, particularly in the inflammatory process in human arthritis.
    Type: Application
    Filed: May 11, 2001
    Publication date: April 25, 2002
    Inventors: Evelyn Murphy, Orla M. Conneely, Oliver Fitzgerald, Barry Bresnihan
  • METHODS FOR TREATMENT AND PREVENTION OF HELICOBACTER PYLORI INFECTION USING LACTOFERRIN
    Publication number: 20020016289
    Abstract: The present invention is directed to methods for using lactoferrin as a therapeutic and/or prophylactic compound to treat and/or prevent infections caused by enteropathogens such as H. pylori. The present invention is directed to the treatment or prevention of diseases and disorders resulting from infection by enteropathogens such as H. pylori including histological gastritis, functional dyspepsia, duodenal ulcers, gastric ulcers, gastric cancer, chronic renal failure, HIV, pernicious anemia, Zollinger-Ellison syndrome and colonic polyps. The present invention is further directed to novel formulations and compositions comprising lactoferrin and pharmaceutically acceptable carriers, excipients and/or adjunct companion therapies such as one or more antibiotics.
    Type: Application
    Filed: February 25, 1999
    Publication date: February 7, 2002
    Inventors: ORLA M. CONNEELY, PAULINE P. WARD, DENIS R. HEADON
  • Production of recombinant lactoferrin and lactoferrin polypeptides using cDNA sequences in various organisms
    Patent number: 6228614
    Abstract: The verified cDNA sequences for human, bovine and porcine lactoferrin protein have been used to prepare recombinant lactoferrin for therapeutic and nutritional applications. Regions of the cDNA such as the Fe binding sites can be used to make an hLF polypeptide product. The present invention provides novel plasmids, transfected eucaryotic cells and methods of producing these plasmids and transfected eucaryotic cells. The novel plasmid contains the cDNA for lactoferrin protein. Methods for the production of lactoferrin protein in fungi and bacteria are also provided. Thus, the present invention provides an efficient and economical means for the production of recombinant lactoferrin protein and lactoferrin related polypeptides.
    Type: Grant
    Filed: March 9, 1999
    Date of Patent: May 8, 2001
    Assignee: Baylor College of Medicine
    Inventors: Orla M. Conneely, Denis R. Headon, Bert W. O'Malley, Gregory S. May
  • Lactoferrin variants and uses thereof
    Patent number: 6111081
    Abstract: The present invention is directed to recombinant nucleic acids encoding lactoferrin variants and portions thereof, having modified iron-binding capacity, and to vectors comprising same recombinant nucleic acids. The present invention is further directed to methods of producing such vectors, and to transfected cells harboring the same. Methods for the production of lactoferrin variants and portions thereof, in various eukaryotic or prokaryotic cells are also provided. Finally, the invention is directed to lactoferrin variants and portions thereof encoded by the nucleic acids of the invention and produced by the processes of the invention. Thus, the invention provides an efficient and economical means for the production of recombinant lactoferrin variants and portions thereof.
    Type: Grant
    Filed: May 30, 1997
    Date of Patent: August 29, 2000
    Assignee: Baylor College of Medicine
    Inventors: Orla M. Conneely, Pauline P. Ward
  • Production for recombinant lactoferrin and lactoferrin polypeptides using DNA sequences in various organisms
    Patent number: 6100054
    Abstract: The verified cDNA sequences for human, bovine and porcine lactoferrin protein have been used to prepare recombinant lactoferrin for therapeutic and nutritional applications. Regions of the cDNA such as the Fe binding sites can be used to make an hLF polypeptide product.The present invention provides novel plasmids, transfected eucaryotic cells and methods of producing these plasmids and transfected eucaryotic cells. The novel plasmid contains the cDNA for lactoferrin protein. Methods for the production of lactoferrin protein in fungi and bacteria are also provided. Thus, the present invention provides an efficient and economical means for the production of recombinant lactoferrin protein and lactoferrin related polypeptides.
    Type: Grant
    Filed: May 30, 1995
    Date of Patent: August 8, 2000
    Assignee: Baylor College of Medicine
    Inventors: Orla M. Conneely, Denis R. Headon, Bert W. O'Malley, Gregory S. May
  • Expression of processed recombinant lactoferrin and lactoferrin polypeptide fragments from a fusion product in Aspergillus
    Patent number: 6080559
    Abstract: The subject invention provides for the production of lactoferrins and lactoferrin polypeptide fragments using the host cells Aspergillus in combination with novel plasmid constructs. More specifically, the subject invention provides novel vector constructs capable of producing lactoferrins and lactoferrin polypeptide fragments in Aspergillus host cells. More particularly, the subject invention provides for novel plasmid constructs suitable for use with Aspergillus and especially Aspergillus awamori, niger and oryzae host cells, which enables them to produce large amounts of recombinant lactoferrins and lactoferrin polypeptide fragments.
    Type: Grant
    Filed: June 29, 1998
    Date of Patent: June 27, 2000
    Assignee: Agennix, Inc.
    Inventors: Orla M. Conneely, Denis R. Headon, Bert W. O'Malley
  • Expression of processed recombinant lactoferrin and lactoferrin polypeptide fragments from a fusion product in aspergillus
    Patent number: 5955316
    Abstract: The subject invention provides for the production of lactoferrins and lactoferrin polypeptide fragments using the host cells Aspergillus in combination with novel plasmid constructs. More specifically, the subject invention provides novel vector constructs capable of producing lactoferrins and lactoferrin polypeptide fragments in Aspergillus host cells. More particularly, the subject invention provides for novel plasmid constructs suitable for use with Aspergillus and especially Aspergillus awamori, niger and oryzae host cells, which enables them to produce large amounts of recombinant lactoferrins and lactoferrin polypeptide fragments.
    Type: Grant
    Filed: August 1, 1996
    Date of Patent: September 21, 1999
    Assignee: Agennix, Inc.
    Inventors: Orla M. Conneely, Denis R. Headon, Bert W. O'Malley
  • Screening system for identifying compounds that regulate steroid and orphan receptors mediation of DNA transcription
    Patent number: 5945279
    Abstract: A tissue culture screening system to monitor a transcriptional response treated by a chemical signal interacting with a plasma membrane receptor is provided. The tissue culture screening system includes a cell line containing a membrane receptor, a target gene and a specific receptor selected from the group consisting of a steroid receptor, a vitamin receptor and an orphan receptor. The specific receptor regulates transcription of the target gene. Any of the target gene membrane receptor or specific receptor can be introduced into the cell by an expression vector. In addition to the screening system there is also provided assays for identifying test compounds and chemical signals that regulate transcription or are potential agonist or antagonist neurotransmitters or which regulate indirectly by a membrane receptor binding or regulate transription in the absence of a steroid, vitamin or orphan ligand. There is further provided kits for the assays.
    Type: Grant
    Filed: June 2, 1995
    Date of Patent: August 31, 1999
    Assignee: Baylor College of Medicine
    Inventors: Bert W. O'Malley, Orla M. Conneely, Ronan F. Power
  • Production of recombinant lactoferrin and lactoferrin polypeptides using cDNA sequences in various organisms
    Patent number: 5849881
    Abstract: The verified cDNA sequences for human, bovine and porcine lactoferrin protein have been used to prepare recombinant lactoferrin for therapeutic and nutritional applications. Regions of the cDNA such as the Fe binding sites can be used to make an hLF polypeptide product.The present invention provides novel plasmids, transfected eucaryotic cells and methods of producing these plasmids and transfected eucaryotic cells. The novel plasmid contains the cDNA for lactoferrin protein. Methods for the production of lactoferrin protein in fungi and bacteria are also provided. Thus, the present invention provides an efficient and economical means for the production of recombinant lactoferrin protein and lactoferrin related polypeptides.
    Type: Grant
    Filed: May 30, 1995
    Date of Patent: December 15, 1998
    Inventors: Orla M. Conneely, Denis R. Headon, Bert W. O'Malley, Gregory S. May
  • Screening system and assay for identifying compounds that regulate steroid and orphan receptors mediation of DNA transcription
    Patent number: 5834213
    Abstract: A tissue culture screening system to monitor a transcriptional response treated by a chemical signal interacting with a plasma membrane receptor is provided. The tissue culture screening system includes a cell line containing a membrane receptor, a target gene and a specific receptor selected from the group consisting of a steroid receptor, a vitamin receptor and an orphan receptor. The specific receptor regulates transcription of the target gene. Any of the target gene membrane receptor or specific receptor can be introduced into the cell by an expression vector. In addition to the screening system there is also provided assays for identifying test compounds and chemical signals that regulate transcription or are potential agonist or antagonist neurotransmitters or which regulate indirectly by a membrane receptor binding or regulate transcription in the absence of a steroid, vitamin or orphan ligand. There is further provided kits for the assays.
    Type: Grant
    Filed: October 1, 1993
    Date of Patent: November 10, 1998
    Assignee: Baylor College of Medicine
    Inventors: Bert W. O'Malley, Orla M. Conneely, Ronan F. Power
  • Production of recombinant lactoferrin and lactoferrin polypeptides using CDNA sequences in various organisms
    Patent number: 5766939
    Abstract: The verified cDNA sequences for human, bovine and porcine lactoferrin protein have been used to prepare recombinant lactoferrin for therapeutic and nutritional applications. Regions of the cDNA such as the Fe binding sites can be used to make an hLF polypeptide product.The present invention provides novel plasmids, transfected eucaryotic cells and methods of producing these plasmids and transfected eucaryotic cells. The novel plasmid contains the cDNA for lactoferrin protein. Methods for the production of lactoferrin protein in fungi and bacteria are also provided. Thus, the present invention provides an efficient and economical means for the production of recombinant lactoferrin protein and lactoferrin related polypeptides.
    Type: Grant
    Filed: May 30, 1995
    Date of Patent: June 16, 1998
    Assignee: Baylor College of Medicine
    Inventors: Orla M. Conneely, Denis R. Headon, Bert W. O'Malley, Gregory S. May
  • Production of recombinant human lactoferrin
    Patent number: 5571896
    Abstract: The present invention provides novel plasmids, transfected eucaryotic cells and methods of producing these plasmids and transfected eucaryotic cells. The novel plasmid contains the cDNA for human lactoferrin protein. Methods for the production of human lactoferrin protein in A. Oryzae are also provided. Thus, the present invention provides an efficient and economical means for the production of recombinant human lactoferrin protein.
    Type: Grant
    Filed: May 27, 1994
    Date of Patent: November 5, 1996
    Assignee: Baylor College of Medicine
    Inventors: Orla M. Conneely, Denis R. Headon, Bert W. O'Malley, Gregory S. May
  • Expression of processed recombinant lactoferrin and lactoferrin polypeptide fragments from a fusion product in Aspergillus
    Patent number: 5571697
    Abstract: The subject invention provides for the production of lactoferrins and lactoferrin polypeptide fragments using the host cells Aspergillus in combination with novel plasmid constructs. More specifically, the subject invention provides novel vector constructs capable of producing lactoferrins and lactoferrin polypeptide fragments in Aspergillus host cells. More particularly, the subject invention provides for novel plasmid constructs suitable for use with Aspergillus and especially Aspergillus awamori, niger and oryzae host cells, which enables them to produce large amounts of recombinant lactoferrins and lactoferrin polypeptide fragments.
    Type: Grant
    Filed: November 2, 1994
    Date of Patent: November 5, 1996
    Assignee: Baylor College of Medicine Texas Medical Center
    Inventors: Orla M. Conneely, Denis R. Headon, Bert W. O'Malley
  • Production of recombinant lactoferrin and lactoferrin polypeptides using CDNA sequences in various organisms
    Patent number: 5571691
    Abstract: The verified cDNA sequences for human, bovine and porcine lactoferrin protein have been used to prepare recombinant lactoferrin for therapeutic and nutritional applications. Regions of the cDNA such as the Fe binding sites can be used to make an hLF polypeptide product.The present invention provides novel plasmids, transfected eucaryotic cells and methods of producing these plasmids and transfected eucaryotic cells. The novel plasmid contains the cDNA for lactoferrin protein. Methods for the production of lactoferrin protein in fungi and bacteria are also provided. Thus, the present invention provides an efficient and economical means for the production of recombinant lactoferrin protein and lactoferrin related polypeptides.
    Type: Grant
    Filed: October 28, 1993
    Date of Patent: November 5, 1996
    Assignee: Baylor College of Medicine
    Inventors: Orla M. Conneely, Denis R. Headon, Bert W. O'Malley, Gregory S. May